



## NEWS RELEASE

---

### **Cost-efficient expansion of key biological data to enhance the validation and value of therapeutic investment propositions**

**London/Manchester, September 21, 2023** - Incubate Bio announces the availability of a novel methodology for the cost-efficient and rapid addition of biological data for promising therapeutic assets. The outcome is a comprehensive understanding of the biological landscape around the target of interest or disease pathway.

Within the life science industry, data drives investment. Adding relevant biological evidence quickly and cost-effectively for a therapeutic in a biotech's portfolio has the potential to improve the value of the asset or platform. In addition, a stronger, more comprehensive data package significantly increases the chance of successfully securing vital follow-on investment.

*"As we all know, biology is complex and any approach that enhances our understanding of disease pathways and crucial targets is very valuable in helping identify the best new therapeutics with the greatest potential,"* commented **Dr Raminderpal Singh, CEO of Incubate Bio.**

To date, the approach has been successfully employed in areas focused on the DNA Damage Repair pathway. One team who have adopted the approach and who are integrating it into their on-going experimental data workflows is **QV Bioelectronics**. Focused on accelerating a new treatment modality for Glioblastoma, **Principal Scientist in Cancer Biology Dr Ashwin Narayanan said:** *"Using ALaSCA, we were able to successfully analyse the contributions of different DNA repair pathways and programmed cell death pathways across several treatment regimes. The causal AI results are helping us narrow down potential mechanism of action of Electric field therapy on glioblastoma cell lines as well as identifying potential targets to test in the future for synergistic therapy."*

Pioneered by leading industry maverick Dr Raminderpal Singh and the expert multidisciplinary team at Incubate Bio, their approach, ALaSCA, combines the best of today's AI and ML techniques to cost-efficiently find, assess, and interpret crucial biological data relevant to a specific asset or pathway. The ALaSCA Cancer Model System performs rapid target assessment by deploying large language models generated from both open access data and company-confidential data and combining these with rigorous multi-causal analysis to provide unique insights and identify vital additional data.

To access ALaSCA and to find out more detailed information, please see <https://www.incubate.bio/>

+++ END +++